Similar to what we reported here, a deficient expression of ASS1 has been previously described to be associated with clinical aggressiveness in myxofibrosarcomas, bladder cancer and nasopharyngeal carcinoma [11–13]. Here, ASS1 is linked to urinary bladder cancer.